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Abstract: Lipid nanocapsules (LNCs) are potential drug carriers for pulmonary delivery since 
they can be nebulized without any structural or functional changes, and the aerosols produced are 
highly compatible with pulmonary drug delivery in human beings. The alveolar surface tension, 
in vitro cytotoxicity, biodistribution and pulmonary toxicity in rats of a single endotracheal spray 
of LNCs or paclitaxel-loaded LNCs were studied. In vitro cytotoxicity of LNCs after a spray 
remained unchanged. Biodistribution study showed a homogeneous repartition in the lungs in 
rats with an improvement in lung retention of the radiolabeled tracer loaded in LNCs compared 
to the absence of LNCs with a lung half-time of 8.8±0.7 hours. Bronchoalveolar fluid analysis 
revealed transient 7-day alveolar inflammation, reaching a maximum between days 2 and 4, 
characterized by a peak of granulocytes at day 1 followed by a peak of lymphocytes at day 3. 
Alveolar protein levels were increased at days 3 and 7. Acute inflammation was increased with 
paclitaxel-loaded LNCs in comparison with blank LNCs but dropped out at day 7. No histological 
pulmonary lesion was observed at day 60. LNCs lowered surface tension to a greater degree than 
Curosurf® in a physicochemical model of the pulmonary alveolus. A single pulmonary delivery 
of LNCs induces a short-term alveolar inflammation with no residual lesions in rats at day 60. 
These data permit to start the study of LNCs in surfactant replacement therapy.
Keywords: lipid nanocapsules, pulmonary drug delivery, biodistribution, toxicity, paclitaxel
Introduction
Lipid nanocapsules (LNCs) are nanometric vectors that can be used to dissolve 
lipophilic drugs without the need of organic solvents or excipients known to have a 
recognized effect.1 They are versatile nano-sized drug carriers able to solubilize highly 
lipophilic drugs and to generate aerosols as paclitaxel (PTX) or fluticasone propionate.2,3 
The produced aerosols are compatible with pulmonary drug delivery in human beings, 
with an aerosol mass median aerodynamic diameter equal to 2.7±0.1 µm and a fine 
particle fraction (between 1.0 and 5.0 µm) of 81.5%±3.1%.4
Pulmonary drug delivery presents a number of advantages to treat chronic lung 
diseases such as asthma, chronic obstructive pulmonary disease or cystic fibrosis, or 
acute diseases such as hyaline membrane disease in preterm neonates.5–8 Aerosolized 
anticancer drugs have potential interests to treat lung adenocarcinoma or lung 
metastases.9 The main advantages are direct access to the zones to be treated, allowing 
a reduction in the doses administered to the patient and consequently a reduction in 
systemic adverse effects. In addition, the pulmonary route has new interest in newborns, 
because it could reduce the potential interactions with the intestinal microbiota and 
could avoid interference with the immune development or the gut–brain axis.10–13
Preclinical toxicological data on LNCs obtained after intravenous administration 
in mice have demonstrated the good safety of these nanocarriers.14,15 On the contrary, 
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published data on some pulmonary drug delivery systems 
have shown acute toxicity in mice. In fact, surface hydropho-
bicity of nanoparticles from 50 to 150 nm was characterized 
by hydrophobic interaction chromatography (HIC). The acute 
lung inflammation was quantified after pulmonary admin-
istration to mice. The correlation between nanomaterial 
HIC index and acute lung inflammation was determined for 
LNCs, polyvinyl acetate and polystyrene nanoparticles. This 
study showed that LNCs have a low HIC index and induce 
little inflammation unlike polyvinyl acetate and polystyrene 
nanoparticles characterized by high HIC index and increase 
acute alveolar toxicity.16 In another study, the relationships 
between nanoparticle hydrophobicity, inflammatory out-
comes and the metabolic fingerprint in bronchoalveolar fluid 
from mice exposed to various nanoparticles were studied 
following a single-dose intratracheal administration. Results 
confirm that particles with high surface hydrophobicity were 
proinflammatory and that adenosine monophosphate (AMP) 
concentration in bronchoalveolar fluid was correlated with 
neutrophilia and nanoparticle surface hydrophobicity.17 
Grabowski et al,18 in a model of human respiratory alveolar 
epithelium cell culture, have clearly demonstrated that the 
inflammation and cell damage induced by these vectors 
are correlated with the surface charge and the nature of the 
nanoparticle core.
The purpose of this study was to determine the potential 
toxicity of a single endotracheal spray of LNCs in rats. 
We studied in vitro cytotoxicity of blank and PTX-loaded 
LNCs (PTX-LNCs), biodistribution and acute and middle-
term pulmonary toxicities of blank and PTX-LNCs in rats 
after a single endotracheal spray. We also studied the alveolar 
surface tension of LNCs on a physicochemical model of the 
pulmonary alveolus.
Materials and methods
Materials
Lipoid® P75-3 (genetically modified organism-free soybean 
lecithin containing 69% of phosphatidylcholine), Captex® 
8000 (glyceryl tricaprylate), Labrafac® CC (caprylic–capric 
acid) and Kolliphor® HS15 (polyethylene glycol ester of 
12-hydroxystearic acid and polyethylene glycol) were 
obtained from Lipoid GmbH (Ludwigshafen, Germany), 
Abitec Corp. (Columbus, OH, USA), Gattefosse SA (St-Priest, 
France) and BASF (Ludwigshafen, Germany), respectively. 
PTX powder and commercial Taxol® 6 mg/mL were pro-
vided by LC Laboratories (Woburn, MA, USA) and Bristol-
Myers Squibb (Rueil-Malmaison, France), respectively. 
Distilled water was obtained from Cooper (Melun, France). 
Sodium chloride (NaCl) was obtained from Prolabo VWR 
International (Fontenay-sous-Bois, France). Sterile saline 
serum was supplied by Aguettant (Lyon, France). Dichlo-
romethane was supplied by Sigma-Aldrich Co. (St Louis, 
MO, USA). Phosphate-buffered saline (PBS) was obtained 
from Lonza (Verviers, Belgium). Ministar® 0.20 µm high-
flow filters from Sartorius AG (Goettingen, Germany) were 
used. Cryo.S cryotubes were purchased from Greiner Bio-One 
(Frickenhausen, Germany). About 4% phosphate-buffered 
formalin was obtained from Labonord (Templemars, France). 
99mTc-pertechnetate (99mTcO
4
−) was obtained by saline elution 
of a 99Mo/99mTc generator (IBA, Paris, France). Excipients 
for the formulation of the 99mTc-super six sulfur lipophilic 
complex were obtained from Chemical Engineering and Mol-
ecules for Life Sciences Platform (Rennes, France). Curosurf® 
was obtained from our academic pharmacy.
lNcs
Preclinical batches of lNcs
The study was performed on LNCs having a mean diameter of 
55 nm and prepared according to a scaled-up protocol that was 
compliant with the original process and allowed the produc-
tion of standard batches for in vivo studies.1,4,19 Briefly, Captex 
8000, Lipoid S75-3, Kolliphor HS15, NaCl and water (12 g, 
672 mg, 10 g, 733 mg and 18 g, respectively) were mixed 
and heated to 90°C under magnetic stirring. Three cycles 
of progressive heating and cooling between 90°C and 70°C 
were then carried out. Thermal exchanges were optimized by 
bathing in water at 95°C and at room temperature. This step 
was followed by an irreversible shock, induced by dilution 
with 112 mL of 0°C deionized water added to the mixture at 
a temperature of 78°C. Magnetic stirring was applied to the 
LNCs suspension for 5 minutes at room temperature, and 
molar sodium hydroxide and NaCl were added (50 µL and 
110 mg, respectively). The dispersion was filtered through a 
0.20 µm Ministar filter into a sterile CRYO.S cryotube. For 
the formulation of PTX-LNCs, 1.8% w/w of PTX powder 
was first solubilized in Captex 8000 under magnetic stirring 
and heated at 50°C for 30 minutes. The procedure described 
earlier was then applied to this mixture. CRYO.S cryotubes, 
previously filled with LNCs dispersion, were frozen in liquid 
nitrogen. Cryotubes were thawed at room temperature for 
30 minutes before use. This procedure allowed to obtain a 
suspension with a concentration of 0.181 mg/mL of PTX.
Batches of radiolabeled lNcs
LNCs loaded with technetium-99m (99mTc-SSS-LNCs) were 
obtained by means of a two-step procedure. The first step 
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consisted of preparation of a 99mTc-SSS complex according 
to a previously described method.20 Briefly, the 188Re-SSS 
complex was obtained by the reaction of the ligand sodium 
dithiobenzoate (Chemical Engineering and Molecules for 
Life Sciences Platform) with a freeze-dried formulation kit 
containing 30 mg of sodium gluconate, 30 mg of ascorbic 
acid, 40 mg of potassium oxalate and 4 mg of SnCl
2
⋅2H
2
O 
reconstituted in 0.5 mL of normal saline. About 1,110 MBq 
of 99mTc-pertechnetate (99mTcO
4
− in 0.5 mL) was added, and 
the solution was mixed for 15 minutes at room temperature. 
About 20 mg of sodium dithiobenzoate (in 0.5 mL, pH =7) 
was then added before heating at 100°C for 30 minutes, 
resulting in the formation of the 99mTc-SSS lipophilic com-
plex. The second step consisted of encapsulation of the newly 
formed 99mTc-SSS complexes in the lipophilic core of the 
nanocapsules. For this purpose, LNCs were prepared accord-
ing to the phase inversion process described earlier.
characterization of lNcs
Size distribution, polydispersity index and zeta potential 
measurements of LNCs dispersions were characterized by 
photon correlation spectroscopy using a Malvern Zetasizer®, 
Nano Series DTS 1060 (Malvern Instruments, Malvern, UK). 
To determine the drug payload, PTX-LNCs dispersions were 
filtered through 0.22 µm Ministar high-flow filters. PTX con-
centrations and encapsulation efficiency were measured in 
the supernatant by high-performance liquid chromatography 
in triplicate experiments according to a previously described 
protocol.14 The same experiments were performed with LNCs 
dispersions after formation of an aerosol.
Formation of lNcs aerosols
Pulmonary nebulization of LNCs in rodents was gener-
ated by means of an endotracheal spray produced by a 
MicroSprayer® Aerosolizer – Model IA-1C-R (Penn-Century, 
Inc., Wyndmoor, PA, USA) according to a previously 
published method.21 Briefly, after isoflurane-induced anesthe-
sia, rats were suspended by their upper incisors. The tip of the 
MicroSprayer Aerosolizer was introduced into the animal’s 
trachea using a pediatric laryngoscope. Aerosol deliveries 
were performed under a fume hood to avoid exposure of the 
operator. The aerosol was collected in a CRYO.S cryotube for 
analysis of the LNCs after passage in the MicroSprayer.
In vitro cytotoxicity study
The in vitro cytotoxicity of thawed LNCs, “sprayed” and 
thawed LNCs, thawed PTX-LNCs and sprayed and thawed 
PTX-LNCs on NCI-H460 human lung cancer cells was 
determined using a growth inhibition assay. A NCI-H460 
human, large cell lung carcinoma cell line was obtained from 
the American Type Culture Collection (ATCC, Manassas, VA, 
USA). Cells were cultured in RPMI 1640 medium containing 
glutamine (Lonza), 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (Sigma-Aldrich Co.), 1 mM 
sodium pyruvate (Lonza), 1.5 g/L sodium bicarbonate 
(Cambrex Biosciences, Verviers, Belgium), 10% fetal bovine 
serum (Lonza), 50 U/mL penicillin and 50 mg/mL strepto-
mycin (Sigma-Aldrich Co.). Cells were routinely maintained 
at 37°C in a humidified atmosphere of 5% CO
2
 in air. The 
culture medium was replaced every 2 or 3 days, and the cells 
were subcultured weekly using 0.25% trypsin – 1 mM EDTA 
(Sigma-Aldrich Co.). Tumor cells were seeded in 24-well 
plates at 50,000 cells/well. All the assays were performed 
with exponentially growing cultures. A drug-containing 
medium was added after 48 hours. A dose range from 10−3 to 
100 nM PTX-LNCs or LNCs formulations was tested for each 
sample. Cytotoxicity was assessed after 2 days of exposure by 
adding 80 µL of CellTiter 96® Aq
ueous
 One Solution Reagent 
(Promega Corporation, Fitchburg, WI, USA) to each well 
according to the manufacturer’s instructions.22,23 After 4 hours 
of culture, cell viability was determined by measuring the 
absorbance at 492 nm using a Multiskan Ascent microplate 
reader (Thermo Fisher Scientific, Waltham, MA, USA). As 
LNCs dispersions are not translucent, the absorbance of wells 
containing the cells was subtracted from the absorbance of 
wells containing culture medium alone for each point. The 
half-maximal inhibitory concentration (IC
50
) of the drug was 
calculated. Three independent experiments were performed 
in triplicate.
animal studies
Experiments were performed in 180 female, 8–10-week-old 
Sprague–Dawley rats weighing 200–300 g (Janvier Labs, Le 
Genest Saint Isle, France) housed in the Angers University 
Hospital animal facility. Animals were provided with food 
and drinking water ad libitum according to a regular 12-hour 
day/night cycle. After 1 week of acclimatization, animals 
were randomized to experimental groups. Following random-
ization, animals were observed and weighed daily. Weight 
loss, the appearance of the fur, respiratory rate, behavior and 
responses to normal stimuli were evaluated daily according 
to the toxicity scale described elsewhere.14 For each animal, 
a single daily endotracheal spray of 200 µL was administered 
during brief isoflurane anesthesia according to a validated 
protocol.21 This volume corresponds to a surface area dose 
of ~2,650 cm2 per animal. The research complied with 
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the European Community guidelines for the protection of 
animals used for scientific purposes. The experimental pro-
tocol was approved by the Pays de la Loire ethics committee 
on animal experiments (number 2011.9), and studies were 
conducted in compliance with French legislation.
Biodistribution study
Six female Sprague Dawley rats were housed in individual 
metabolism cages for the collection of urine and feces. For 
the biodistribution studies, 15 MBq of the LNCs-99mTc-SSS 
suspension (n=4) or the 99mTc-pertechnetate solution 
(99mTcO
4
−Na+) as control (n=2) was administered by the endo-
tracheal spray technique (15 MBq/200 µL) in xylazine- and 
isoflurane-anesthetized healthy Wistar rats. Static acquisi-
tions were obtained at the times 10 minutes, 1 hour, 3 hours 
and 22 hours using a SOPHA DSX γ-camera (Sopha Medical 
Vision, Buc, France) dedicated to animal studies. A scout 
view was acquired on a GE LightSpeed system (GE Health-
care UK Ltd, Little Chalfont, UK) and fused with the planar 
scintigraphy of the same animal for anatomical localization of 
the LNCs-99mTc-SSS and the 99mTcO
4
− distributions. For this 
purpose, the acquired images were analyzed and processed on 
a Xeleris 2 workstation (GE Healthcare). Regions of interest 
(ROIs) were drawn manually on various organs (lungs, liver, 
stomach, spleen, trachea) on the planar images. Time–activity 
curves for the LNCs-99mTc-SSS- and the 99mTcO
4
− control-
injected rats were obtained by plotting the ROIs on the images 
for the various acquisition times. The activity in the ROI was 
expressed as a percentage of the injected dose. To compare 
the lung clearance (Cl) kinetics of the LNCs-99mTc-SSS and 
the 99mTcO
4
− controls, several pharmacokinetic parameters 
such as lungs’ half-life (T
1/2
), mean residence time (MRT) 
and Cl were calculated using a non-compartmental model 
for the analysis of the pharmacokinetics data (Kinetica 5.1 
software; Thermo Fisher Scientific).
Lung wet/dry weight and lung/body weight ratios and 
histological examination
Exploratory analysis of lung wet/dry weight and lung/body 
weight ratios was designed to determine the duration and 
intensity of any pulmonary inflammation induced by the vari-
ous aerosols.24 Animals were randomized in 19 groups of six 
rats: one control group receiving no spray, six groups receiving 
one saline serum spray, six groups receiving one blank LNCs 
spray and six groups receiving one PTX-LNCs spray. A batch 
of animals from each group was sacrificed on days 1 (24 hours 
after endotracheal spray), 2, 4, 7, 21 and 60. Each animal was 
weighed before sacrifice, and the fresh weight of the lungs 
was determined after sacrifice. Necropsy (thorax + abdomen + 
pelvis) was performed on each animal at the time of sacrifice. 
Light microscopy histological examination of the lungs was 
performed on the animals of the three groups sacrificed on day 
60. Lungs were fixed in 50% formalin for histological exami-
nation. About 5 µm paraffin-embedded and hematoxylin–
eosin–saffron-stained sections were analyzed according to a 
previously published score.14 This score assessed lung inflam-
mation in four lung sectors: peribronchiolar, perivascular, 
interstitial and alveolar. For each sector, the histopathological 
aspect was scored on a scale of 0 (no change: normal aspect), 
1 (mild inflammation: dispersed mononuclear leukocytes), 2 
(moderate inflammation: presence of one to three nodules of 
mononuclear leukocytes) and 3 (severe inflammation: more 
than three nodules of mononuclear leukocytes). The final score 
was the sum of the highest scores observed in each sector 
of the lungs. The researchers who examined the slides were 
blinded to the treatments received by the rats. A total of 114 
animals were included in this study.
Bronchoalveolar lavage (Bal) examination
Animals were randomized to 10 groups of six rats: one 
control group receiving no spray, three groups receiving one 
saline serum spray, three groups receiving one blank LNCs 
spray and three groups receiving one PTX-LNCs spray. BAL 
was performed on a batch of animals from each group on 
days 1 (24 hours after endotracheal spray), 3 and 7. After 
sacrifice by inhalation of 5% CO
2
, BAL was performed on 
both lungs in the following way: the trachea was surgically 
exposed and incised transversely to introduce a metal cannula 
with a watertight seal. Two aliquots of 7.5 mL of PBS were 
then injected. The fluid was re-aspirated with the syringe. 
BAL fluid was then centrifuged at 1,500 rpm at 4°C, and 
the pellet was recovered and suspended in 250 µL of PBS. 
Global alveolar cellularity was determined by counting on 
a Malassez cell. The differential cell count was determined 
after centrifugation and smearing on a slide with a Cytospin 
4 and Hematoxylin -Eosin -Saffron (HES) staining. At least 
100 cells were counted to determine the proportion of mac-
rophages, neutrophils, eosinophils and lymphocytes. The 
lipid index of foamy macrophages was calculated according 
to Hopkins et al.25 Briefly, Oil red O staining was performed 
in BAL cells. The red vacuoles of 100 consecutive mac-
rophages were scored from 0 to 4 (0: absence of staining, 1: 
presence of one to three intracellular distinct lipid droplets, 
2: more than three distinct lipid droplets, 3: multiple conflu-
ent droplets with visible nucleus, 4: complete opacifications 
of the cytoplasm with obscuration of the nucleus). The lipid 
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index was computed as the summation for all scores. The 
researchers who examined the slides were blinded to the 
treatments received by the 60 rats. The supernatant was 
collected for the assay of total alveolar protein by the BCA 
protein assay kit (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer’s instructions.
Study of alveolar surface tension
Alveolar surface tension was studied by means of a pendant-
drop tensiometer (Tracker; IT Concept, Longessaigne, 
France) based on the captive bubble model.26–28 The 5 µL 
bubble was immersed in a saline bath at 37°C. Surface ten-
sion was measured under static conditions for 3 minutes 
to determine the equilibrium surface tension and the time 
required to achieve this equilibrium for four solutions: saline; 
50 µg/mL Curosurf; 50 µg/mL Kolliphor HS15 or LNCs at 
a concentration equivalent to 50 µg/mL of Kolliphor HS15. 
Equilibrium adsorption data are expressed as time, and mini-
mum surface tension is expressed in mN/m. The results of 
three independent experiments are presented (mean ± SD).
Statistical analysis
Results are expressed as mean ± SD. A Kruskal–Wallis test 
was used to determine statistical significance, completed by a 
Mann–Whitney U-test. In every case, p,0.05 was considered 
to be significant. SPSS version 19 software (IBM Corpora-
tion, Armonk, NY, USA) was used for statistical analysis.
Results
characteristics of batches of lNcs
The structural characteristics of blank LNCs and PTX-LNCs 
after thawing and passage in the MicroSprayer Aerosolizer 
are presented in Table 1. The mean particle sizes of thawed 
blank LNCs, thawed and sprayed blank LNCs, thawed PTX-
LNCs, thawed and sprayed PTX-LNCs and radiolabeled 
LNCs were 65.5, 65.6, 65.2, 65.0 and 55.9, respectively. 
The polydispersity indexes of thawed blank LNCs, thawed 
PTX-LNCs and radiolabeled LNCs were 0.039, 0.039 and 
0.038, respectively. These indexes were increased to 0.126 
and 0.107 after passage in the MicroSprayer Aerosolizer for 
thawed blank LNCs and thawed PTX-LNCs, respectively. The 
zeta potentials of the dispersions were found between −6.9 
and −9.3 mV. For drug-loaded nanocarriers, the PTX payload 
was equal to 1.6±0.1 mg/mL after thawing and remained 
unchanged after passage in the MicroSprayer Aerosolizer.
In vitro cytotoxicity study
The results of cytotoxicity assays are presented in Figure 1 
and Table 1. The IC
50
 of PTX was 3.1 nM, as published 
elsewhere (4.8 nM).29 The IC
50
 values of thawed blank 
LNCs, thawed and sprayed blank LNCs, thawed PTX-LNCs 
and thawed and sprayed PTX-LNCs were 2.1, 2.1, 2.4 and 
2.3 nM, respectively.
animal studies
The endotracheal spray procedure did not induce any mortal-
ity. All animals resumed a normal behavior immediately after 
waking. No pathological respiratory or general signs were 
observed in the animals. The daily toxicity score was equal 
to 0 for each rat on each day. Weight gain was observed in all 
the animals after administration of the spray until the day of 
sacrifice, with no significant difference between the groups. 
In view of the concentration of the LNCs formulations, the 
administration of 200 µL of spray corresponds to a mass dose 
Table 1 characterization of lNcs batches
Formulation 
group
Mean 
particle 
size (nm)
Polydispersity 
index
Zeta 
potential 
(mV)
IC50 (nM)
Thawed blank lNcs 65.5±0.2 0.039±0.005 −6.9±0.3 2.1
Thawed and 
sprayed blank LNCs
65.6±2.5 0.126±0.008 −8.4±0.2 2.1
Thawed PTX-lNcs 65.2±0.8 0.039±0.005 −7.9±0.3 2.4
Thawed and 
sprayed PTX-LNCs
65.0±0.4 0.107±0.007 −7.8±0.9 2.3
radiolabeled lNcs 55.9±0.6 0.038±0.008 −9.3±0.6 –
Note: experiments were performed in triplicate.
Abbreviations: Ic50, half-maximal inhibitory concentration; LNCs, lipid 
nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs.
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Figure 1 Growth inhibition assay of Taxol®, thawed LNCs, thawed and sprayed 
LNCs, thawed PTX-LNCs and thawed and sprayed PTX-LNCs on NCI-H460 cell 
growth.
Note: This result shows that the Ic50 is equal.
Abbreviations: Ic50, half-maximal inhibitory concentration; LNCs, lipid nanocapsule; 
PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs.
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of ~36 µg per animal and a surface area of about ~2,650 cm2 
for the two lungs.
Biodistribution study
Only a low level of the radioactivity deposition in the 
trachea (6.08%±1.14% and 11.15%±2.99%, respectively) 
was observed following the endotracheal administration of 
the LNCs-99mTc-SSS (n=4) or the 99mTcO
4
− solution (n=2). 
As expected, 10 minutes after the administration of the LNCs-
99mTc-SSS or the 99mTcO
4
−, the static planar scintigraphic 
acquisitions combined with scout scans revealed distribution 
of both tracers in the lungs. However, subsequent acquisitions 
(1, 3 and 22 hours post injection) showed dramatic changes 
between the distribution of the LNCs-99mTc-SSS and the 
99mTcO
4
− (Figure 2A and B). Time–activity curves extracted 
from the scintigraphic acquisition provided details regarding 
tracer distribution kinetics following endotracheal admin-
istration (Figure 3). Lung Cl kinetics of LNCs-99mTc-SSS 
appeared to be slow with a lung T
1/2
 of 8.8±0.7 hours, an MRT 
of 12.9±0.9 hours and a Cl of 0.087±0.007 h−1 (Figure 3A), 
whereas the lung Cl of 99mTcO
4
− was significantly faster with 
a T
1/2
=3.4±1.0 hours (p=0.0013), an MRT of 4.9±1.4 hours 
(p=0.001) and a Cl of 0.273±0.068 h−1 (p=0.0036; Figure 3B). 
The lung Cl of the LNCs-99mTc-SSS was concomitant with an 
increase in radioactivity in the liver. In contrast, the stomach 
was the first elimination organ detected after the Cl of the 
99mTcO
4
− from the lungs.
Animal’s lung wet/dry weight and lung weight/body 
weight ratios
The lung wet/dry weight ratios were not significantly differ-
ent between the groups from day 1 to 60 (data not shown). 
The study of the animal’s lung weight/body weight ratio is 
shown in Figure 4. This ratio was significantly higher in the 
blank NCL spray and PTX-LNCs spray groups by day 1 
compared to the control group. This increased ratio reached 
a maximum between days 2 and 4 and returned to normal 
on day 7 and was comparable to that observed in the control 
group on days 21 and 60. By applying the rule of three Rs to 
animal experimentation, we therefore decreased the number 
of animal analyses by removing the day 21 and day 60 groups 
and by pooling the day 2 and day 4 groups into a single day 3 
group for BAL examinations.
BAL fluid analysis
The median volume of BAL fluid recovered from lavaged 
rat lungs was 13.5±0.5 mL, and no difference was observed 
between groups and days. All BAL fluids were clear. The 
total alveolar cell count is shown in Figure 5. A signifi-
cantly higher total alveolar cell count was observed in the 
PTX-LNCs spray group compared to the control group 
on days 1 and 3. The alveolar differential cell count is 
described in Table 2. No eosinophil was observed in BAL. 
An increased proportion of granulocytes (neutrophils) was 
observed on day 1 in all the groups compared to the control 
group. The highest proportion of granulocytes was observed 
in the PTX-LNCs spray group. On day 3, the proportion of 
granulocytes decreased and the proportion of lymphocytes 
then increased. On day 7, the proportions of the various cells 
returned to baseline. Three examples of BAL are shown in 
Figure 6. Foamy macrophages were observed since day 1 but 
were no longer seen on day 7. Lipid index was calculated on 
days 1 and 3 (Figure 7). Examples of foamy macrophages 
are shown in Figure 8. Total protein assay is illustrated in 
Figure 9. Results indicate an increase in the total alveolar 
cells on the PTX-LNCs spray group only at day 1.
Necropsy and long-term histological examination
Follow-up of the animals until day 60 did not demonstrate 
any clinical or behavioral abnormalities. No macroscopic 
PLQXWHV KRXU KRXUV KRXUV
PLQXWHV KRXU KRXUV KRXUV
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%
Figure 2 Scout view on a GE LightSpeed system fused with the planar scintigraphy 
of the same animal for the anatomical localization of the lNcs-99mTc-sss (A) and the 
99mTc-pertechnetate distributions (B) at 10 minutes, 1 hour, 3 hours and 22 hours 
following the unique endotracheal spray technique administration.
Notes: The successive acquisitions showed the lung distribution of the lNcs-99mTc-
sss (A) and a lung Cl significantly slowed compared to the control (B). The extra-
pulmonary distribution of the LNCs-99mTc-SSS is considerably reduced compared 
to the control.
Abbreviations: Cl, clearance; LNCs, lipid nanocapsule.
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Absence of lung fibrosis after a single pulmonary delivery of LNCs
abnormality of the lungs, heart, kidneys, liver, spleen, ovaries 
or gastrointestinal tract was observed on necropsy examina-
tions. No lymph node hypertrophy or pleural, pericardial or 
peritoneal effusion was observed. Histological examination 
of the lungs removed on day 60 did not reveal any signs 
of pulmonary toxicity according to a previously published 
histopathological score (Table 3).14 Typical pulmonary 
lesions are shown in Figure 10.
Surface tension analysis
Analysis of alveolar surface tension is shown in Figure 11. 
The surface tension on the captive bubble was not modified 
by the addition of saline. The addition of Kolliphor HS15 
(50 µg/mL) and Curosurf (50 µg/mL) lowered captive 
bubble surface tension from about 70.3±0.4 to 47.4±0.5 
and 46.2±0.4 mN/m after 360 seconds, respectively. The 
addition of LNCs, at a concentration equivalent to 50 µg/mL 
of Kolliphor HS15, lowered captive bubble surface tension 
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Figure 3 Time–activity curves for LNCs-99mTc-sss (A) and 99mTc-pertechnetate control-injected rats (B).
Notes: The error bars are too small to be seen over the time. These curves showed a lung retention of activity with LNCs, whereas there was a faster Cl with the controls. 
Vascular corresponds to an rOI on the thigh muscle.
Abbreviations: Cl, clearance; LNCs, lipid nanocapsule; ROI, region of interest.
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Figure 4 Mean ± SD of lung/body weight ratio for the control group (no spray), 
the saline serum spray group, the blank LNCs spray group and the PTX-LNCs spray 
group at days 1, 2, 4, 7, 21 and 60 (n=6).
Notes: Results indicate an increase in the ratio at days 1, 2 and 4 in the blank LNCs 
and PTX-LNCs groups. At days 7, 21 and 60, no difference is observed. *p,0.05 
versus the control group. **p,0.01 versus the control group.
Abbreviations: LNCs, lipid nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded 
lNcs.
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Figure 5 Mean ± SD of total alveolar cells for the control group (no spray), the 
saline serum spray group, the blank LNCs spray group and the PTX-LNCs spray 
group at days 1, 3 and 7 (n=6).
Notes: results indicate an increase in the total alveolar cells on the PTX-lNcs 
spray group only at days 1 and 3. At day 7, no difference is observed. **p,0.01 
versus the control group.
Abbreviations: LNCs, lipid nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded 
lNcs.
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from about 70 to 42.0±0.5 mN/m after 360 seconds (p,0.05 
versus Kolliphor HS15 and Curosurf).
Discussion
In this study, we studied the pulmonary drug delivery of 
a single endotracheal spray of LNCs or PTX-LNCs in 
rats. This study compiles data on the in vitro cytotoxicity 
analysis of LNCs and PTX-LNCs after spray generation by 
a MicroSprayer Aerosolizer, the biodistribution of LNCs 
after a spray in rats’ lungs, the alveolar toxicity of a single 
endotracheal spray in rats of LNCs and PTX-NCL and the 
60-day toxicity analysis. Exploratory study of the surfac-
tant potential of LNCs on a physicochemical model of the 
pulmonary alveolus is also described. The results are the 
absence of structural degradation or loss of cytotoxicity 
of LNCs and PTX-LNCs after passage in a MicroSprayer 
Aerosolizer, a predominant biodistribution of LNCs in the 
lungs of the rats with a lungs’ half-life of 8.8±0.7 hours, a Cl 
of 0.087±0.007 h−1 after pulmonary delivery, an initial and 
transient alveolar inflammation reflected by hypercellularity 
and increased total proteins in BAL fluid and the absence of 
lung tissue lesions observable under light microscopy 60 days 
after a single endotracheal dose.
We first confirm previous results concerning the ability 
of LNCs to remain structurally and functionally unchanged 
after aerosol generation with the MicroSprayer Aerosolizer.16 
This procedure has been used in many studies to reproduc-
ibly deposit a large volume of solution of interest in the deep 
lung of rodents.21,30,31 The volume of 200 µL was chosen, 
because it corresponds to the maximum volume that can be 
administered to rats. This procedure was well tolerated and 
did not cause any death.
Instead of the classical ex vivo studies, a noninvasive 
approach, based on sequential planar scintigraphic imaging, 
was preferred to monitor, after endotracheal administration, 
the 99mTc-LNCs-SSS biodistribution. This method was cho-
sen on the basis of a preliminary unpublished study, which 
showed that .90% of the radiolabeled LNCs remained 
localized in the lungs after a single spray. In this study, early 
acquisitions (t =10 min) confirmed the good performance of 
the endotracheal technique for the administration of the LNCs 
suspensions. Lung deposition appeared to be more effective, 
Table 2 Macrophage, lymphocyte and granulocyte counts in cells/mm3 in Bal (percentage in parentheses) in the four groups at 
days 1, 3 and 7
Formulation group Day 1 Day 3 Day 7
Control group (no spray) M: 978±156 (95±1)
l: 51±20 (5±1)
g: 0±0 (0±0)
Saline serum spray group M: 965±144 (92±4)
l: 29±26 (3±2)
g: 58±58 (5±5)*
M: 1,249±490 (95±3)
l: 51±51 (4±4)
g: 9±9 (1±1)
M: 1,028±174 (95±3)
l: 44±29 (4±2)
g: 14±14 (1±1)
Blank LNCs spray group M: 817±313 (68±6)
l: 39±54 (3±3)
g: 344±118 (29±8)**
M: 1,065±273 (90±4)
l: 92±66 (7±5)
g: 25±25 (3±3)
M: 1,157±403 (95±2)
l: 54±30 (4±2)
g: 4±4 (1±1)
PTX-LNCs spray group M: 1,164±176 (61±10)
l: 144±101 (7±5)
g: 676±401 (32±11)**
M: 2,296±955 (88±3)**
l: 242±127 (9±3)**
g: 91±48 (3±2)**
M: 1,074±311 (95±1)
l: 41±14 (4±1)
g: 11±11 (1±1)
Notes: *p,0.05 versus the control group. **p,0.01 versus the control group. Data presented as mean ± sD.
Abbreviations: BAL, bronchoalveolar lavage; G, granulocyte; L, lymphocyte; LNCs, lipid nanocapsule; M, macrophage; PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs.
Figure 6 BAL smears after fixation and HES staining (40×).
Notes: (A) Control group rat: the cells are predominantly macrophages. (B) In a rat, 24 hours after PTX-LNCs spray: numerous granulocytes (arrows). All granulocytes 
were polymorphonuclear neutrophils. (C) In a rat 72 hours after PTX-LNCs spray: marked regression of the granulocyte population and appearance of lymphocytes 
(arrowheads). Stars indicate foamy macrophages.
Abbreviations: BAL, bronchoalveolar lavage; LNCs, lipid nanocapsule; HES, Hematoxylin-Eosin-Saffron; PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs.
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Absence of lung fibrosis after a single pulmonary delivery of LNCs
with far less mouth or throat deposition, as compared to the 
administration technique by oral aspiration.32 The lungs’ 
time–activity curves revealed the slow pulmonary Cl of LNCs 
and confirmed the potential value of LNCs to deliver drugs of 
interest into the deep lung. This slow lung Cl of radioactivity 
was not observed with the control animals (.70% versus 
32% of the dose is still present in the lung at t =22 hours). 
Moreover, the discrepancies in organ biodistribution between 
the 99mTc-LNCs-SSS and the controls clearly demonstrate 
the effect of LNCs on the behavior of the drug (ie, 99mTc). 
Indeed, after the lung Cl, 99mTcO
4
− control animals showed 
an accumulation of the tracer in the stomach (which is a 
classic uptake organ for 99mTcO
4
−), whereas 99mTc-LNCs-SSS 
showed only an accumulation in the liver, which indicates 
that a portion of LNCs (ie, 21.4% at t =22 hours) was able to 
cross the air–blood barrier and reach the systemic circulation 
before its uptake by mononuclear phagocytic system (MPS) 
organs such as liver.
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Figure 7 Lipid index in BAL at days 1 and 3 in the four groups.
Note: *p=0.05 versus the saline serum spray group.
Abbreviations: BAL, bronchoalveolar lavage; LNCs, lipid nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs.
Figure 8 Oil red O staining of three macrophages from BAL at day 1 in the PTX-
LNCs spray group (immersion, ×100).
Note: each macrophage was scored at 3.
Abbreviations: BAL, bronchoalveolar lavage; LNCs, lipid nanocapsule; PTX, 
paclitaxel; PTX-LNCs, PTX-loaded LNCs.
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Figure 9 Mean ± SD of total proteins for the control group (no spray), the saline 
serum spray group, the blank LNCs spray group and the PTX-LNCs spray group at 
days 1, 3 and 7 (n=6).
Notes: results indicate an increase in the total alveolar cells on the PTX-lNcs 
spray group only at day 1. At days 3 and 7, no difference is observed. *p,0.05 versus 
the control group.
Abbreviations: LNCs, lipid nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded 
lNcs.
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Table 3 Histopathological scores by anatomical compartments of the lungs in the three groups at day 60
Formulation group Peribronchial 
compartment
Perivascular 
compartment
Interstitial 
compartment
Alveolar 
compartment
Global 
score
Saline serum spray group 1.8±0.4 1.0±0.0 0.3±0.8 0.0±0.0 3.2±0.4
Blank LNCs spray group 1.8±0.4 1.2±0.4 0.2±0.4 0.0±0.0 3.2±0.4
PTX-LNCs spray group 1.5±0.5 1.2±0.4 0.0±0.0 0.0±0.0 2.7±0.5
Kruskal–Wallis test Ns Ns Ns Ns Ns
Notes: No significant difference is observed. Data presented as mean ± sD.
Abbreviations: LNCs, lipid nanocapsule; PTX, paclitaxel; PTX-LNCs, PTX-loaded LNCs; NS, not significant. 
The low level of the extrapulmonary distribution should 
reduce the risk of systemic toxicity. Patel et al32 studied this 
parameter in mice and showed that 50 nm LNCs adminis-
tered by oral aspiration were retained by the lungs with a 
half-life of 10.5 hours (which is consistent with our results) 
and that moderate pulmonary inflammation did not reduce 
the pulmonary Cl of LNCs.
This study mainly focused on the detection of tissue 
lesions, such as pulmonary fibrosis, 60 days after endotra-
cheal spray of LNCs in rats, as the absence of such lesions 
provides essential information in terms of preclinical safety. 
We looked for signs of acute alveolar inflammation by means 
of three parameters: lung weight/body weight ratio, changes 
in alveolar cell populations and changes in total alveolar 
proteins, reflecting tissue edema, cell influx and alveolar 
injury, respectively. We then performed light microscopy 
examination of the lungs to determine whether this inflam-
mation resolved without leaving any tissue “sequelae” or 
whether it progressed to chronic inflammation. We did not 
study the immunological mechanisms involved in this inflam-
mation (immune cell populations, cytokines and interleukin 
networks). This study is important, as particles with a large 
surface area/mass ratio can induce local toxicity via tissue 
inflammation, which can then induce tissue fibrosis. Jones 
et al16 published the first toxicity study after pulmonary 
administration of 25 µL of 50 nm LNCs at a dose of 0.8 or 
8 mg/mL per lung in mice. This study showed no changes 
in alveolar cell populations and an increase in total alveolar 
proteins at the highest dose 24 hours after endotracheal spray 
delivered by a MicroSprayer Aerosolizer. Unlike Jones et al, 
we observed signs of alveolar inflammation, and this differ-
ence can be explained by the choice of the dose administered 
and the choice of animal species. We used undiluted LNCs 
and PTX-LNCs formulations, corresponding to a more than 
10-fold higher surface area dose than the highest concentra-
tion used by Jones et al.16 This concentration difference could 
explain the absence of toxicity in the study by Jones et al 
and the presence of toxicity in our study. We chose such a 
high concentration, because highly concentrated solutions 
allow the use of small nebulization volumes, resulting in 
shorter nebulization times for the patient. We have shown 
that the only commercial apparatus able to nebulize LNCs 
is the eFlow® rapid.4 This apparatus has a 3 mL reservoir 
and takes 8.4 minutes to nebulize the volume of LNCs used 
in this study. We believe that the concentrations used in the 
studies by Jones et al were too low compared to the doses of 
Figure 10 Light microscopy histological examination of the lungs on day 60 after 
fixation and HES staining (20×).
Notes: (A) Example of perivascular nodule of mononuclear leukocytes (star). 
(B) Example of a peribronchiolar nodule of mononuclear leukocytes (arrow).
Abbreviation: HES, Hematoxylin-Eosin-Saffron.
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Figure 11 evolution of surface tension on the captive bubble versus time after the 
addition of saline serum, 50 µg/ml of curosurf®, 50 µg/ml of Kolliphor® hs15 and 
lNcs at a concentration equivalent to 50 µg/ml Kolliphor hs15.
Notes: Isotherms were obtained by monitoring adsorption of the mixtures in the 
captive bubble tensiometer at 37°c. Data are mean ± sD of three independent 
experiments. The error bars are too small to be seen over the time. *p,0.05 
versus the Kolliphor HS15 and Curosurf. This figure illustrates the greater capacity 
of lNcs to reduce the surface tension on the captive bubble than curosurf and 
Kolliphor hs15 alone.
Abbreviation: lNcs, lipid nanocapsule.
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Absence of lung fibrosis after a single pulmonary delivery of LNCs
LNCs required in aerosol therapy. Furthermore, in contrast 
to Jones et al who took mice, our studies were conducted 
in rats, as the Organization for Economic Cooperation and 
Development recommends conducting acute lung toxicity 
studies in 8–12-week-old rats that have been acclimatized for 
at least 5 days.33 Rats appear to be more sensitive than mice 
or hamsters to the risk of pulmonary fibrosis.34 Our decision 
to perform this study in rats was therefore well adapted to 
the objective of this study.
In this study, we minimized the causes of exogenous pul-
monary inflammation. We removed the excess of Kolliphor 
HS15 stabilizer by 0.22 µm filtration, which also allowed 
sterilization of the final LNCs and PTX-LNCs solutions 
before storage. Sterile normal saline was also used. We have 
previously demonstrated the pyrogen-free nature of the LNCs 
formulation.4 Despite these precautions, it is noteworthy 
that simple endotracheal spray of normal saline induced a 
transient alveolar inflammatory reaction on day 1 in the rats 
of the saline serum group. The results of this study appear 
to justify the initiation of chronic toxicity studies in rats, 
which must look for the presence of chronic inflammation, 
pulmonary fibrosis and lipid accumulation. We did not inves-
tigate possible accumulation of lipids in the lungs, as lipid 
accumulation requires chronic exposure to inhaled lipids. 
We observed a higher proportion of foamy macrophages in 
the blank LNCs and PTX-LNCs groups than in the control 
and saline serum spray groups on day 1. The proportion of 
foamy macrophages then decreased on day 3, and they were 
no longer visible on day 7. These findings demonstrated 
progressive elimination of part of the lipids delivered in the 
aerosol by alveolar macrophages over the 7 days following 
endotracheal spray. Furthermore, Patel et al32 showed that 
the alveolar inflammation induced by LNCs did not modify 
the pulmonary Cl of these particles in mice, and therefore 
did not increase the risk of accumulation of the components 
of LNCs, particularly lipids, following the administration 
of a single dose.
Finally, we confirm that LNCs have surfactant property.35 
We demonstrated that this property was more effective 
than the tensio-active component alone of the LNCs (Kol-
liphor HS15) and the commercial animal-derived surfac-
tant Curosurf.
Conclusion
A single pulmonary delivery of blank LNCs or PTX-LNCs 
induces a short-term alveolar inflammation with no residual 
lesions in rats at day 60. These results indicate that LNCs is 
a potential drug carrier for pulmonary delivery of PTX.
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